Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

149 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
[Epidemiology of acne].
Schäfer T, Kahl C, Rzany B. Schäfer T, et al. Among authors: kahl c. J Dtsch Dermatol Ges. 2010 Mar;8 Suppl 1:S4-6. doi: 10.1111/j.1610-0387.2009.07167.x. J Dtsch Dermatol Ges. 2010. PMID: 20482691 Review. German.
[Epidemiology of acne vulgaris].
Rzany B, Kahl C. Rzany B, et al. Among authors: kahl c. J Dtsch Dermatol Ges. 2006 Jan;4(1):8-9. doi: 10.1111/j.1610-0387.2005.05876.x. J Dtsch Dermatol Ges. 2006. PMID: 16503926 German.
[S3-Guidelines for the therapy of psoriasis vulgaris].
Nast A, Kopp IB, Augustin M, Banditt KB, Boehncke WH, Follmann M, Friedrich M, Huber M, Kahl C, Klaus J, Koza J, Kreiselmaier I, Mohr J, Mrowietz U, Ockenfels HM, Orzechowski HD, Prinz J, Reich K, Rosenbach T, Rosumeck S, Schlaeger M, Schmid-Ott G, Sebastian M, Streit V, Weberschock T, Rzany B; Germany Society for Dermatology. Nast A, et al. Among authors: kahl c. J Dtsch Dermatol Ges. 2006 Nov;4 Suppl 2:S1-126. doi: 10.1111/j.1610-0387.2006.06172.x. J Dtsch Dermatol Ges. 2006. PMID: 17187649 German. No abstract available.
Evidence-based (S3) guidelines for the treatment of psoriasis vulgaris.
Nast A, Kopp IB, Augustin M, Banditt KB, Boehncke WH, Follmann M, Friedrich M, Huber M, Kahl C, Klaus J, Koza J, Kreiselmaier I, Mohr J, Mrowietz U, Ockenfels HM, Orzechowski HD, Prinz J, Reich K, Rosenbach T, Rosumeck S, Schlaeger M, Schmid-Ott G, Sebastian M, Streit V, Weberschock T, Rzany B; Deutsche Dermatologische Gesellschaft (DDG); Berufsverband Deutscher Dermatologen (BVDD). Nast A, et al. Among authors: kahl c. J Dtsch Dermatol Ges. 2007 Jul;5 Suppl 3:1-119. doi: 10.1111/j.1610-0387.2007.06172.x. J Dtsch Dermatol Ges. 2007. PMID: 17615051
German evidence-based guidelines for the treatment of Psoriasis vulgaris (short version).
Nast A, Kopp I, Augustin M, Banditt KB, Boehncke WH, Follmann M, Friedrich M, Huber M, Kahl C, Klaus J, Koza J, Kreiselmaier I, Mohr J, Mrowietz U, Ockenfels HM, Orzechowski HD, Prinz J, Reich K, Rosenbach T, Rosumeck S, Schlaeger M, Schmid-Ott G, Sebastian M, Streit V, Weberschock T, Rzany B. Nast A, et al. Among authors: kahl c. Arch Dermatol Res. 2007 Jun;299(3):111-38. doi: 10.1007/s00403-007-0744-y. Epub 2007 May 12. Arch Dermatol Res. 2007. PMID: 17497162 Free PMC article. Review.
[Hair loss or pseudo hair loss].
Mleczko A, Garcia Bartels N, Kahl C, Blume-Peytavi U. Mleczko A, et al. Among authors: kahl c. J Dtsch Dermatol Ges. 2007 Nov;5(11):1031-3. doi: 10.1111/j.1610-0387.2007.06393.x. J Dtsch Dermatol Ges. 2007. PMID: 17976145 German. No abstract available.
[Pustular psoriasis].
Weisenseel P, Wilsmann-Theis D, Kahl C, Reich K, Mössner R. Weisenseel P, et al. Among authors: kahl c. Hautarzt. 2016 Jun;67(6):445-53. doi: 10.1007/s00105-016-3804-4. Hautarzt. 2016. PMID: 27240667 Review. German.
Relevance of different prognostic scores in primary CNS lymphoma in the era of intensified treatment regimens: A retrospective, multicenter analysis of 174 patients.
Zeremski V, Adolph L, Beer S, Berisha M, Jacobs B, Kahl C, Koenecke C, Kropf S, Panse J, Petersen J, Schmidt-Hieber M, Schneider J, Vucinic V, Walter J, Weigert O, Witte HM, Mougiakakos D. Zeremski V, et al. Among authors: kahl c. Eur J Haematol. 2024 Apr;112(4):641-649. doi: 10.1111/ejh.14159. Epub 2024 Jan 2. Eur J Haematol. 2024. PMID: 38164819
FOLFOXIRI Plus Cetuximab or Bevacizumab as First-Line Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer: The Randomized Phase II FIRE-4.5 (AIO KRK0116) Study.
Stintzing S, Heinrich K, Tougeron D, Modest DP, Schwaner I, Eucker J, Pihusch R, Stauch M, Kaiser F, Kahl C, Karthaus M, Müller C, Burkart C, Reinacher-Schick A, Kasper-Virchow S, Fischer von Weikersthal L, Krammer-Steiner B, Prager GW, Taieb J, Heinemann V. Stintzing S, et al. Among authors: kahl c. J Clin Oncol. 2023 Sep 1;41(25):4143-4153. doi: 10.1200/JCO.22.01420. Epub 2023 Jun 23. J Clin Oncol. 2023. PMID: 37352476 Clinical Trial.
149 results